The Institute of Clinical Research (ICR) is the probably the oldest independent membership-led professional body for global clinical researchers.
For over 40 years, The Institute of Clinical Research (ICR) has provided high quality training, networking and support to the clinical research community. For many Members the Institute has been part of their life throughout their working careers, many have been with the Institute since its first incarnation as the ACRPI.
It is the membership that makes the Institute.
How does it all work ?
The Institute of Clinical Research is you, the Membership governed by the Articles of Memorandum drawn up by the founding members.
The Board is made up of members who give their time freely to guide the future direction of the ICR.
The ICR Secretariat is the administrative arm of the Institute, its primary focus is to ensure that the wishes of the Board and Membership are carried out and to see to the day to day tasks that any membership organisation generates.
The ICR exists to support our members through all stages of their careers. We do this, in part, by:
The biotechnology industry begins 2023 at a crossroads.
In many ways, the sector is coming off of one of its toughest years in recent memory. Initial …
The FDA is making some changes in the accelerated approval process. In this episode, we’ll discuss the recent changes with the FDA’s regulation of can…
Sometime before the end of March, a person with the inherited blood disease beta thalassemia will receive an infusion containing hundreds of millions …
As the corporate world evolves in the wake of COVID-19, Sanofi has christened an innovative headquarters to help keep pace.
For cell and gene therapies, all stages of the drug development life cycle are complex. The patient, product and supply chain requires specialized set…
Pfizer’s chief executive Albert Bourla, Ph.D., is in hot water for claims he made during a BBC interview late last year about the company's then-unapp…
The Food and Drug Administration has started the first regulatory review of a gene therapy for Duchenne muscular dystrophy, the treatment’s developer,…
Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875…
For cell and gene therapies, all stages of the drug development life cycle are complex. The patient, product and supply chain requires specialized set…
Phase 1 research will evaluate tolerability and safety of therapy among healthy volunteers
Infex – a company focusing on anti-infectives specialist – …
What a long, strange trip it’s been for teplizumab, a drug developed to combat juvenile diabetes—36 years to be exact.
GSK will stop selling the drug Zejula for some ovarian cancer patients whose disease is stable after a second line of chemotherapy, the company said F…
Many researchers are surprised to find that leaving university also means leaving behind something they didn’t expect—easy access to peer-reviewed lit…
An experimental Alzheimer’s disease medicine from Roche failed two large Phase 3 clinical trials, a major setback to the Swiss company’s yearslong eff…
Move over, COVID: Shots to stop respiratory syncytial virus (RSV) are providing the new must-watch trial data on Twitter as healthcare influencers on …
The workforce reduction is part of a “new strategic direction” for Galapagos, which intends to stop developing drugs for fibrosis and kidney disease.
With an FDA approval 19 months ago to treat chronic kidney disease, AstraZeneca’s Farxiga dominated the race against its primary SGLT2 rival—Eli Lilly…
Pfizer is considering hiking the price of its COVID-19 vaccine by roughly four times what it currently charges as it prepares for sales in the U.S. to…
Education and support are critical to getting—and keeping—patients on appropriate therapy. But many oncology patients have gaps in their knowledge of …
Blood tests could help guide the treatment of children with the cancer rhabdomyosarcoma (RMS), according to a new study led by scientists at the Insti…
How do you solve a problem like Elon Musk? Well, when it comes to his weight, there seems to be a simple answer: Novo Nordisk’s Wegovy.
With a thumbs up from Europe’s Committee for Medicinal Products for Human Use (CHMP), Atara Biotherapeutics’ Ebvallo is poised to become the first all…
The companies will aim to improve treatment for patients with prostate, breast and lung cancer
The Innovative Medicines Initiative (IMI) – a joint und…
Eisai and Biogen's Alzheimer’s disease drug lecanemab did surprisingly well in a phase 3 trial. The results support the idea that an anti-amyloid drug…
All of our delegates and members who had course places postponed over the last two years due to covid restrictions/illness have now been contacted dir…
Online payments currently temporarily suspended. To make a payment please contact <a href="http://office@icr-global.org/" style="backgroun...
Online payments currently temporarily suspended. To make a payment please contact office@icr-global.org&n...
Online payments currently temporarily suspended. To make a payment please contact <a href="http://office@icr-global.org/" style="background-...
Online payments currently temporarily suspended. To make a payment please contact <a href="http://office@icr-global.org/" style="background-...
Online payments currently temporarily suspended. To make a payment please contact <a href="http://office@icr-global.org/" style="background-...
Online payments currently temporarily suspended. To make a payment please contact <a href="http://office@icr-global.org/" style="backgroun...